Medicamen Biotech

What Medicamen Biotech does

Medicamen Biotech Limited (BSE-listed, ticker MBL) is an Indian vertically integrated pharmaceutical company that develops, manufactures and exports generic drugs, with a strategic focus on oncology finished dosage forms including lyophilized and ready-to-use sterile injectables and oral solid dosage forms. The company operates four manufacturing and R&D sites — a general FDF facility in Bhiwadi, Rajasthan (est. 1993) housing a DSIR-approved R&D center; Haridwar Unit-I for general formulations (2007); Haridwar Unit-II dedicated to oncology injectables and oral solids (2021); and a 538,195 sqft USFDA-approved API facility at Dahej, Gujarat operated by parent company Shivalik Rasayan Limited.

Its product portfolio spans eight therapeutic segments: oncology (primary), cardiology, CNS, diabetology, anti-infective, anti-malarial, vitamins/supplements and pain management, though oncology is the dominant vertical and growth driver. Technically, the company is differentiated by in-house formulation development for complex oncology molecules — most notably BORTEZOMIB, for which it filed its first US FDA Abbreviated New Drug Application (ANDA) in July 2023 backed by an internally developed Active Pharmaceutical Ingredient with a USFDA-filed Drug Master File.

Medicamen makes money primarily through B2B pharmaceutical product sales — both finished dosage forms and APIs — distributed through domestic oncology marketing targeting healthcare professionals and hospitals, alongside direct international exports to 35+ countries across the Americas, Africa, Asia and Australia. Regulatory compliance is its commercial backbone: USFDA approvals (sterile injectables Haridwar 2024; Dahej API 2024; oncology plant audit completed April 2023), EU GMP certification for Bhiwadi (2024), plus WHO, PAHO, ANVISA, NAFDAC and other country registrations enable access to regulated markets. FY26 revenue was Rs 197.77 crore (~$23.5M, +21.67% YoY) with FY26 net profit of Rs 9.64 crore (+35.58%); the company also owns subsidiary Medicamen Lifesciences (launched 2022), which extends the group into antihypertensive, antidiabetic and cardiology manufacturing across eight additional facilities.

Name

Medicamen Biotech

Legal name

Medicamen Biotech Limited

Website

https://medicamen.com

Company type

Public

Founded year

1993

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Medicamen Biotech Limited is an Indian vertically integrated pharmaceutical company that develops, manufactures and exports generic oncology drugs (sterile injectables and oral solids) and APIs to 35+ countries, operating USFDA- and EU GMP-certified facilities in Bhiwadi and Haridwar under parent Shivalik Rasayan Limited.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Drug Product Fill-Finish & Aseptic Manufacturing Services (HLAAAKAB), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

Keywords

• Pharmaceutical manufacturing
• Oncology generics
• Active pharmaceutical ingredients
• Sterile injectables
• Finished dosage forms

Headquarters

HQ city

New Delhi

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Manufacturing and sale of pharmaceutical products including oncology drugs, generic medications across multiple therapeutic segments. Revenue from domestic Indian market and exports to 35+ countries worldwide.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels2 records

Core offering

Medicamen Biotech Limited manufactures, supplies, and exports Active Pharmaceutical Ingredients (APIs), general Finished Dosage Forms (FDF), and specialized oncology formulations including Lyophilized (Lyo) and Ready-to-Use (RTU) sterile injectables plus oral solid dosage forms. The company operates four state-of-the-art manufacturing facilities (Bhiwadi, Haridwar Unit-I, Haridwar Unit-II, and Dahej API plant) approved by USFDA, EU GMP, and other international regulators, selling into the Indian domestic market and exporting to 35+ countries.

Product overview

Medicamen Biotech is an integrated pharmaceutical company offering a comprehensive portfolio of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDF). The company operates across multiple therapeutic areas including Oncology (Cancer Care), Cardiology, CNS, Diabetology, Anti-Infective, Anti-Malarial, Vitamins & Supplements, and Pain Management. The core product offerings consist of: (1) APIs manufactured at USFDA-approved Dahej facility under parent company Shivalik Rasayan Limited, (2) General FDF manufactured at EU GMP-certified Bhiwadi facility and Haridwar Unit-I, (3) Specialized oncology injectables (Lyo & RTU) and oral solid dosage forms at Haridwar Unit-II, and (4) DSIR-approved R&D services developing products for global regulated markets. The company has achieved significant regulatory milestones including USFDA approvals and EU GMP certification, positioning it as a emerging global player in affordable oncology generics.

Differentiator

Problem solved

Functional benefit

Products and services

• Cancer Care (Oncology) Pharmaceuticals Comprehensive oncology pharmaceutical products including targeted therapies for solid tumors and hematology cancers, focused on affordable cancer care treatments for hospitals and patients.
• Cardiology Pharmaceuticals Pharmaceutical products for the diagnosis and treatment of heart-related diseases and disorders.
• Central Nervous System (CNS) Pharmaceuticals Pharmaceutical products targeting the central nervous system including brain and spinal cord conditions.
• Diabetology Pharmaceuticals Specialized medications for the study, diagnosis, and management of diabetes mellitus.
• Anti-Infective / Antibiotic Pharmaceuticals Antibiotics and antimicrobial medications used to treat bacterial infections by killing or inhibiting bacteria growth.
• Anti-Malarial Pharmaceuticals Drugs used to prevent and treat malaria, a mosquito-borne infectious disease caused by Plasmodium parasites.
• Vitamins & Supplements Organic compounds essential for proper body functioning, playing crucial roles in various physiological processes.
• Pain Management Pharmaceuticals Medications and treatments for managing pain, an unpleasant sensory and emotional experience associated with actual or potential tissue damage.
• Active Pharmaceutical Ingredients (APIs) Manufacturing of high-quality Active Pharmaceutical Ingredients including oncology and non-oncology molecules at the USFDA-approved Dahej facility under parent company Shivalik Rasayan Limited.
• Finished Dosage Forms (FDF) - General Formulations Finished pharmaceutical products manufactured at Bhiwadi (established 1993) and Haridwar Unit-I (established 2007) facilities covering multiple therapeutic areas.
• Finished Dosage Forms (FDF) - Oncology Injectables Specialized oncology injectables including Lyophilized (Lyo) and Ready-to-Use (RTU) products plus oral solid dosage forms manufactured at Haridwar Unit-II (established 2021).
• Pharmaceutical Research & Development Services DSIR-approved R&D center at Bhiwadi campus conducting Chemical, Analytical and Formulation R&D, with 60+ scientists developing products for regulated markets.
• BORTEZOMIB Injection (3.5 MG/VIAL) Oncology generic injection product for multiple myeloma treatment, for which Medicamen filed its first ANDA with USFDA.

Quantifiable outcome

• Operating profit margin turned positive at 8.97% from negative 5.44% in prior year period
• +1 more outcomes

Segments8 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Medicamen LifesciencescoreOthers · 23 October 2022Subsidiary of MEDICAMEN BIOTECH launched in 2022. Specializes in manufacturing and marketing of pharmaceutical products with focus on Anti-hypertensives, Antidiabetics, and Cardiology treatments. Operates eight manufacturing facilities compliant with WHO, EU-GMP, and USFDA standards.
• Shivalik Rasayan LimitedcoreOthersParent company of Medicamen Biotech Limited. Responsible for manufacturing BORTEZOMIB API and other Active Pharmaceutical Ingredients. Operates USFDA-approved global API manufacturing facility at Dahej, Gujarat. Led by Chairman Rahul Bishnoi.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Sun Pharmaceutical Industries: India's largest pharma company with oncology portfolio, USFDA-approved injectables, and global regulatory stature. Highly comparable business model (vertically integrated generic injectables) but at vastly larger scale and stronger brand equity in oncology.
• Glenmark Pharmaceuticals: Indian pharma with oncology franchise, USFDA approvals, and broad generics portfolio across multiple therapeutic areas matching Medicamen's segmentation approach (oncology, cardiology, CNS, diabetology).
• Dr. Reddy's Laboratories: One of India's largest generic manufacturers with significant oncology portfolio (Reddy's already markets Bortezomib in India) and global regulatory footprint. Comparable on oncology generics in regulated markets, though at much larger scale (~Rs 25,000+ cr).
• Cipla: Largest Indian pharma by domestic share with broad oncologics presence, including Bortezomib injections. Comparable on Indian oncology generics competition though operates at substantially larger scale with established oncologist relationships.
• Aurobindo Pharma: Top-5 Indian generic player with USFDA-approved sterile injectable capacity and oncology portfolio. Comparable in regulated-market injectable oncology manufacturing and vertical integration from API to FDF.
• Alkem Laboratories: Large Indian generic pharma with broad therapeutic-area portfolio including oncology and domestic field-sales force advantage. Medicamen VP Subir Chopra is ex-Alkem, and Alkem is a direct competitor in cardiology and oncology. Comparable by therapeutic breadth and Indian market orientation.
• Cadila Healthcare (Zydus): Major Indian pharma with oncology generics, multiple USFDA facilities, and direct competition in cardiology and oncology segments. Comparable in USFDA-regulated injectable manufacturing and broad therapy coverage in India.

Direct peers

• Shilpa Medicare: Indian vertically integrated pharma with strong oncology injectables/CDMO franchise, multiple USFDA/EU GMP facilities, and directly comparable manufacturing footprint (Lyo + RTU sterile injectables). Medicamen's Director Dr. Vimal Shrawat is the ex-COO of Shilpa Medicare, making this the most operationally comparable peer.
• Natco Pharma: Indian pharma specializing in oncology generics and complex formulations with strong USFDA compliance record and domestic oncology brand presence. Natco competes head-to-head with Medicamen in the affordable oncology generics niche in India and ROW markets.

Emerging players

• Intas Pharmaceuticals: Indian pharma with rapidly growing oncology + biosimilars (Bevacizumab, Rituximab) franchise and significant USFDA capacity. Closely comparable trajectory — Indian-headquartered, oncology-centric, USFDA push — though now at much larger revenue scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/medicamen

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medicamen Biotech